Kabelitz D, da Silva Lobo M L, Pechhold K
Institut für Immunologie, Universität Heidelberg.
Klin Wochenschr. 1991 Sep 3;69(13):623-8. doi: 10.1007/BF01649326.
The clinical success of organ transplantation depends to a large degree on the immunological acceptance of the grafted organ. This paper summarizes from an immunological point of view the recent progress that has been made to improve graft acceptance, and discusses some future aspects in the field. Over the last few years, major emphasis has been put on the development of new immunosuppressive drugs, including FK 506, rapamycin, and Deoxyspergualin. Together with monoclonal antibodies against defined T-cell surface antigens, there are now new and effective means available to prevent or treat rejection episodes. Progress has also been made in the field of HLA typing, where the introduction of molecular biology-based methods significantly increased the accuracy of HLA class II typing. The ultimate goal of transplantation immunology is the induction of (donor-) specific tolerance. While some protocols are effective in inducing peripheral tolerance in experimental animals, these regimens are at present not yet applicable in the clinical situation. To overcome the shortage of donor organs, alternative strategies are currently being considered. Among these, xenotransplantation may eventually prove successful, despite the massive immunological problems such as, e.g., the presence of preformed xenoreactive antibodies.
器官移植的临床成功在很大程度上取决于移植器官的免疫耐受。本文从免疫学角度总结了在提高移植物耐受性方面取得的最新进展,并探讨了该领域未来的一些方面。在过去几年中,主要重点一直放在开发新的免疫抑制药物上,包括FK 506、雷帕霉素和去氧精胍菌素。与针对特定T细胞表面抗原的单克隆抗体一起,现在有了预防或治疗排斥反应的新的有效方法。在HLA分型领域也取得了进展,基于分子生物学方法的引入显著提高了HLA II类分型的准确性。移植免疫学的最终目标是诱导(供体)特异性耐受。虽然一些方案在实验动物中有效诱导外周耐受,但目前这些方案尚未适用于临床情况。为了克服供体器官短缺的问题,目前正在考虑替代策略。其中,异种移植最终可能会成功,尽管存在大量免疫问题,例如存在预先形成的异种反应性抗体。